The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease

New England Journal of Medicine

Volumn 334, Issue 7, 1996, Pages 420-425

  Ifudu, Onyekachi ^a,b   Feldman, Joseph ^a   Friedman, Eli A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b and Maimonides Medical Center Jaffe Stroke Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; TRANSFERRIN; UREA;

ADULT; AGED; ANEMIA; ARTICLE; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

AGED; ANEMIA; BLOOD UREA NITROGEN; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOM ALLOCATION; REGRESSION ANALYSIS; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 0030021933     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199602153340702     Document Type: Article

References (31)

1. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989,35:134-48.
2. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease results of a phase III multicenter clinical trial Ann Intern Med 1989;111:992-1000
3. Koch KM, Patyna WD, Shaldon S, Werner E. Anemia of the regular hemodialysis patient and its treatment. Nephron 1974;12:405-19
4. Lundin AP. Quality of life: subjective and objective improvements with recombinam human erythropoietin therapy Semin Nephrol 1989;9:Suppl 1: 22-9
5. Powe NR, Griffiths RI, Greer JW, et al. Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 1993;43:1125-33
6. Powe NR, Griffiths RI, de Lissovoy G, et al Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. JAMA 1992,268:5434-40.
7. Southeastern Kidney Council 1992 annual report. Raleigh, N.C.: Southeastern Kidney Council, 1992.
8. Ifudu O, Mayers J, Matthew J, Tan CC, Cambridge A, Friedman EA Dismal rehabilitation in geriatric inner-city hemodialysis patients, JAMA 1994;271 29-33.
9. Ifudu O, Paul H, Mayers JD, et al. Pervasive failed rehabilitation in center-based maintenance hemodialysis patients. Am J Kidney Dis 1994,23.394-400.
10. Goodnough LT, Strasburg D, Riddell J IV, Verbrugge D, Wish J Has recombmant human erythropoietin therapy minimized red-cell transfusions in hemodialysis patients? Clin Nephrol 1994;41:303-7.
11. Ifudu O, Macey LJ, Friedman EA. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients. ASAJO J 1995,41.M426-M430.
12. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35:712-6.
13. Held PJ, Carroll CE, Liska DW, Turenne MN, Port FK. Hemodialysis therapy in the United States: what is the dose and does it matter? Am J Kidney Dis 1994,24:974-80.
14. Kopple JD, Hakim RM, Held PJ, et al. Recommendations for reducing the high morbidity and mortality of United States maintenance dialysis patients the National Kidney Foundation. Am J Kidney Dis 1994;24:968-73.
15. Consensus Development Conference Panel. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Ann Intern Med 1994; 121:62-70.
16. Markson JL, Rennie JB. The anaemia of chronic renal insufficiency: the effect of serum from azotaemic patients on the maturation of normoblasts in suspension cultures Scot Med J 1956;1:320-2
17. Wallner SF, Vautrin RM. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 1981;97 170-8.
18. Radtke HW, Rege AB, LaMarche MB, et al Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest 1981;67:1623-9.
19. Essers U, Muller W, Heintz R Effect of erythropoietin in normal men and m patients with renal insufficiency. Proc Eur Dialysis Transplant Assoc 1974,11 398-402.
20. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979;93:449-58.
21. Ortega JA, Malekzadeh MH, Dukes PP, et al. Exceptionally high serum erythropoietin activity in an anephric patient with severe anemia. Am J Hematol 1977,2:299-306.
22. McGonigle RJS, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984;25:430-6.
23. Eschbach JW, Adamson JW, Cook JD. Disorders of red blood cell production in uremia. Arch Intern Med 1970;126:812-5.
24. Zappacosta AR, Caro J, Erslev A. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis: the role of erythropoietm. Am J Med 1982;72:53-7.
25. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994;23:661-9.
26. Norusis MJ. SPSS for windows: advanced statistics, release 6.0. Chicago: Statistical Package for the Social Sciences, 1993:1-30.
27. Ingelfinger JA, Mosteller F, Thibodeau LA, Ware JH. Biostatistics in clinical medicine. 3rd ed. New York: McGraw-Hill, 1994:166.
28. Ifudu O, Chan E, Friedman EA. Low hematocrit indicates recent inadequate maintenance hemodialysis. Clin Res 1994;42:263A abstract.
29. Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to recombinant human erythropoieun in normal and uremic subjects. Kidney Int 1992;42:407-16.
30. Rao DS, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-5.
31. Bia MJ, Cooper K, Schnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989;36: 852-8